Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | ATP4A | P20648 | 1/20 | 0.51 |
| ▸ | ATP4B | P51164 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.42 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2537170 | 0.83 | LMNA (0.45) | POLBL3MBTL1CTDSP1MEN1KMT2A | |
| SCHEMBL2537961 | 0.83 | POLB (0.44) | POLBL3MBTL1CTDSP1MEN1KMT2A | |
| SCHEMBL18760498 | 0.80 | LMNA (0.73) | POLBL3MBTL1CTDSP1MEN1KMT2A | |
| Fenclorim SCHEMBL20564320 | 0.80 | LMNA (0.73) | POLBL3MBTL1CTDSP1MEN1KMT2A | |
| Fenclorim SCHEMBL126683 | 0.80 | LMNA (0.73) | POLBL3MBTL1CTDSP1MEN1KMT2A | |
| SCHEMBL2539831 | 0.78 | LMNA (0.63) | POLBL3MBTL1CTDSP1MEN1KMT2A | |
| SCHEMBL7381679 | 0.77 | LMNA (0.68) | POLBL3MBTL1CTDSP1MEN1KMT2A | |
| SCHEMBL16398644 | 0.76 | L3MBTL1 (0.55) | POLBL3MBTL1CTDSP1MEN1KMT2A | |
| SCHEMBL10645121 | 0.76 | LMNA (0.61) | POLBL3MBTL1CTDSP1MEN1KMT2A | |
| SCHEMBL423874 | 0.75 | KDM4E (0.66) | POLBL3MBTL1CTDSP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8466156-B2 | 2-phenyl-4-cyclopropyl-pyrimidine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-06-18 | — | — | US | disclosed |
| EP-1893634-B1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-12-21 | — | — | EP | disclosed |
| EP-2283011-B1 | 2-PHENYL-4-CYCLOPROPYL-PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2011-11-23 | — | — | EP | disclosed |
| US-8048881-B2 | Uding 4-aminocarbonyl-pyrimidine; vascular disorders; cardiovascular disorders; thrombosis; brain disorders; vision defects | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-11-01 | — | — | US | disclosed |
| US-8044055-B2 | 2-phenyl-6-aminocarbonyl-pyrimidine derivatives and their use as P2Y12 receptor | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-10-25 | — | — | US | disclosed |
| CN-101998953-A | 2-phenyl-4-cyclopropyl-pyrimidine derivatives | ACTELION PHARMACEUTICALS LTD | 2011-03-30 | — | — | CN | disclosed |
| EP-2283011-A1 | 2-PHENYL-4-CYCLOPROPYL-PYRIMIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2011-02-16 | — | — | EP | disclosed |
| US-20110028484-A1 | 2-PHENYL-4-CYCLOPROPYL-PYRIMIDINE DERIVATIVES | VIATRIS ASIA PACIFIC PTE. LTD. (SG) | 2011-02-03 | — | — | US | disclosed |
| EP-2079711-B1 | 2-PHENYL-6-AMINOCARBONYL-PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-01-06 | — | — | EP | disclosed |
| US-20090291962-A1 | 2-PHENYL-6-AMINOCARBONYL-PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-11-26 | — | — | US | disclosed |
| WO-2009125365-A1 | 2-PHENYL-4-CYCLOPROPYL-PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-10-15 | — | — | WO | disclosed |
| EP-2079711-A2 | 2-PHENYL-6-AMINOCARBONYL-PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-07-22 | — | — | EP | disclosed |
| US-20080194576-A1 | Pyrimidine Derivatives and Their Use as P2Y12 Receptor Antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-08-14 | — | — | US | disclosed |
| WO-2008050301-A2 | 2- PHENYL- 6-AMINOCARBONYL- PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-05-02 | — | — | WO | disclosed |
| EP-1893634-A2 | PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006114774-A2 | PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291962-A1 | 2-PHENYL-6-AMINOCARBONYL-PYRIMIDINE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR | P2RY12, P2RY13, P2RY2 | POLB 2712/4885L3MBTL1 4034/4885CTDSP1 3673/4885 |
| US-20080194576-A1 | Pyrimidine Derivatives and Their Use as P2Y12 Receptor Antagonists | P2RY12, P2RY13, P2RY4 | POLB 2315/4885L3MBTL1 3765/4885CTDSP1 2858/4885 |
| US-20110028484-A1 | 2-PHENYL-4-CYCLOPROPYL-PYRIMIDINE DERIVATIVES | P2RY12, P2RY13, P2RY4 | POLB 3634/4885L3MBTL1 3731/4885CTDSP1 2846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.